Engineering epigenetic therapy for sickle cell disease
Engineering epigenetic therapy for sickle cell disease
批准号:
8752559
负责人:
CARL D NOVINA
金额:
$86.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-18 至 2019-08-30
关键词:
AdultAgeBiochemicalBiomedical ResearchBirthBlood VesselsCD34 geneCell divisionChemokine (C-C Motif) Receptor 5Clinical TrialsCustomDNADNA BindingDNA Binding DomainDNA MethylationDNA Modification ProcessDiseaseEctopic ExpressionEngineeringEnzymesEpigenetic ProcessErythrocytesFetal HemoglobinGene ActivationGene ExpressionGene SilencingGene TargetingGenesGeneticGenetic EngineeringGlobinHIVHemoglobinHistone AcetylationHistonesIndividualInvestigational New Drug ApplicationKnock-outLeadLiteratureMedicalMethylationModificationMutationNeoadjuvant TherapyPainPhase I Clinical TrialsProcessProteinsResistanceSickle Cell AnemiaSiteT-LymphocyteTechnologyTreatment EfficacyZinc Fingersbasedemethylationfetalgamma Globingene correctiongene therapyhomologous recombinationinnovationinterestknockout genemedical complicationnucleaseprogramsresearch studyrestriction enzymesicklingtechnology developmenttherapeutic gene
中文摘要
描述(由申请人提供):融合到限制性内切酶的定制DNA结合域的出现改变了
英文摘要
DESCRIPTION (provided by applicant): The advent of custom built DNA binding domains fused to restriction enzymes changed the
landscape of biomedical research and heralded a new age in gene therapy. This fact is highlighted by
Phase I clinical trials in which zinc finger nucleases are being used to knockout the CCR5 receptor in
CD34+ T cells of HIV infected individuals to generate HIV-resistant T cells (clinical trial #NCT00842634).
In addition to targeted gene knockout, other biomedical applications of the “designer nucleases” are
gene correction and gene activation. However, gene correction requires homologous recombination
following a DNA cut – a very inefficient process – and current strategies for stable gene activation require
constitutive expression of an ectopic protein, limitations that are likely to hinder therapeutic efficacy. In
contrast to endogenous gene editing or genetic activation, I propose to develop a platform for epigenetic
reprogramming of any locus of interest.
As a proof-of-concept for this technology, I propose to engineer site-specific DNA binding module
fusions with DNA demethylating enzymes for epigenetic induction of fetal hemoglobin (HbF) for therapy
of sickle cell disease (SCD). SCD is caused by mutation of the adult -globin gene which forces red
blood cells to sickle and occlude small blood vessels leading to exquisite pain and a wide range of
medical complications. Fetal hemoglobin is normally silenced at birth by DNA methylation of the -globin
locus as adult hemoglobin increases. Because small increases in HbF can cure this disease, SCD is an
optimal application for developing epigenetic re-programming technologies.
The major advantage of epigenetic engineering is that successful DNA demethylation of CpGs on
both strands will lead to durable HbF-induction, not requiring continuous expression of ectopic proteins.
This highly-innovative strategy has no precedent in the SCD literature. Development of this technology
will lead to potent and durable HbF-induction therapy for SCD that will become the basis for an
investigational new drug application. Moreover, this technology can be adapted to epigenetic
reprogramming of other biochemical modifications including DNA methylation and histone acetylation
and methylation. Each of these modifications could be targeted for therapeutic gene silencing or
activation which will revolutionize molecularly-directed therapy for a variety of diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lnc'ing White Fat to Brown Fat Thermogenesis
-
批准号:10064214
-
项目类别:
-
资助金额:$88.5万
-
财政年份:2020
-
负责人:CARL D NOVINA
-
依托单位:
Defining LncRNA Function in normal and Shwachman Diamond Syndrome Myelopoiesis
-
批准号:10320386
-
项目类别:
-
资助金额:$44.13万
-
财政年份:2019
-
负责人:CARL D NOVINA
-
依托单位:
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
-
批准号:8851544
-
项目类别:
-
资助金额:$69.26万
-
财政年份:2014
-
负责人:CARL D NOVINA
-
依托单位:
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
-
批准号:8687169
-
项目类别:
-
资助金额:$60.31万
-
财政年份:2014
-
负责人:CARL D NOVINA
-
依托单位:
Engineering epigenetic therapy for sickle cell disease
-
批准号:8930980
-
项目类别:
-
资助金额:$86.5万
-
财政年份:2014
-
负责人:CARL D NOVINA
-
依托单位:
Dysregulated microRNA function in diamond blackfan anemia
-
批准号:8734422
-
项目类别:
-
资助金额:$34.58万
-
财政年份:2013
-
负责人:CARL D NOVINA
-
依托单位:
Dysregulated microRNA function in diamond blackfan anemia
-
批准号:8439603
-
项目类别:
-
资助金额:$34.77万
-
财政年份:2013
-
负责人:CARL D NOVINA
-
依托单位:
Dysregulated microRNA function in diamond blackfan anemia
-
批准号:9115159
-
项目类别:
-
资助金额:$34.77万
-
财政年份:2013
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8700331
-
项目类别:
-
资助金额:$31.7万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8895074
-
项目类别:
-
资助金额:$32.68万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8508194
-
项目类别:
-
资助金额:$30.72万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8320147
-
项目类别:
-
资助金额:$32.68万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
Analysis of cap-dependent translational repression by microRNAs in oncogensis
-
批准号:8187439
-
项目类别:
-
资助金额:$32.68万
-
财政年份:2011
-
负责人:CARL D NOVINA
-
依托单位:
A B-CELL SPECIFIC COFACTOR OF NUCLEOSOME REMODELING
-
批准号:6510063
-
项目类别:
-
资助金额:$4.81万
-
财政年份:2002
-
负责人:CARL D NOVINA
-
依托单位:
A B-CELL SPECIFIC COFACTOR OF NUCLEOSOME REMODELING
-
批准号:6372930
-
项目类别:
-
资助金额:$4.2万
-
财政年份:2001
-
负责人:CARL D NOVINA
-
依托单位:
A B-CELL SPECIFIC COFACTOR OF NUCLEOSOME REMODELING
-
批准号:6137099
-
项目类别:
-
资助金额:$3.75万
-
财政年份:2001
-
负责人:CARL D NOVINA
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: